Lukas R. Woltereck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lukas R. Woltereck has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Furtwängler
The Finsen Laboratory, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen
1 shared publication - Brian C. Searle
Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio, USA
1 shared publication - Erwin Marten Schoof
Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark
1 shared publication - Samuel Grégoire
Computational Biology Unit, de Duve Institute, Université Catholique de Louvain
1 shared publication - Teeradon Phlairaharn
The Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen
1 shared publication - Valdemaras Petrosius
Technical University of Denmark
1 shared publication
Latest Publications
- Open Access
High sensitivity limited material proteomics empowered by data-independent acquisition on linear ion traps
In recent years, the concept of cell heterogeneity in biology has gained increasing attention, concomitant with a push towards technologies capable of resolving such biological complexity at the molecular level. For single-cell proteomics using Mass Spectrometry (scMS) and low-input proteomics experiments, the sensitivity of an orbitrap mass analyzer can sometimes be limiting. Therefore, low-input proteomics and scMS could benefit from linear ion traps, which provide faster scanning speeds and higher sensitivity than an orbitrap mass analyzer, however at the cost of resolution. We optimized an acquisition method that combines the orbitrap and linear ion trap, as implemented on a tribrid instrument, while taking advantage of the high-field asymmetric waveform ion mobility spectrometry (FAIMS) pro interface, with a prime focus on low-input applications. First, we compared the performance of orbitrap-versus linear ion trap mass analyzers. Subsequently, we optimized critical method parameters for low-input measurement by data-independent acquisition (DIA) on the linear ion trap mass analyzer. We conclude that linear ion traps mass analyzers combined with FAIMS and Whisper™ flow chromatography are well-tailored for low-input proteomics experiments, and can simultaneously increase the throughput and sensitivity of large-scale proteomics experiments where limited material is available, such as clinical samples and cellular sub-populations.
Open AccessHigh sensitivity limited material proteomics empowered by data-independent acquisition on linear ion traps
In recent years, the concept of cell heterogeneity in biology has gained increasing attention, concomitant with a push towards technologies capable of resolving such biological complexity at the molecular level. For single-cell proteomics using Mass Spectrometry (scMS) and low-input proteomics experiments, the sensitivity of an orbitrap mass analyzer can sometimes be limiting. Therefore, low-input proteomics and scMS could benefit from linear ion traps, which provide faster scanning speeds and higher sensitivity than an orbitrap mass analyzer, however at the cost of resolution. We optimized an acquisition method that combines the orbitrap and linear ion trap, as implemented on a tribrid instrument, while taking advantage of the high-field asymmetric waveform ion mobility spectrometry (FAIMS) pro interface, with a prime focus on low-input applications. First, we compared the performance of orbitrap-versus linear ion trap mass analyzers. Subsequently, we optimized critical method parameters for low-input measurement by data-independent acquisition (DIA) on the linear ion trap mass analyzer. We conclude that linear ion traps mass analyzers combined with FAIMS and Whisper™ flow chromatography are well-tailored for low-input proteomics experiments, and can simultaneously increase the throughput and sensitivity of large-scale proteomics experiments where limited material is available, such as clinical samples and cellular sub-populations.